(*R*)-*N*-hydroxy-4-(6-(((*1R*,*2S*)-2-(hydroxymethyl)-2-methylcyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide, and
(*R*)-4-(6-(((*1R*,*2R*)-2-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-*N*-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

or a salt of such compound.

16. A compound of formula I as defined in one of claims 1 to 15, or a pharmaceutically acceptable salt thereof for use as a medicament.

17. A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

18. Use of a compound of formula I as defined in one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a bacterial infection.

19. The use according to claim 18, wherein the bacterial infection is a Gram-negative bacterial infection.